Irmela Jeremias

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 105 publications

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes.

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes.

Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026

Author Correction: The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.

Author Correction: The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.

Journal: Nature communications
Published: June 11, 2026

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Author Correction: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Journal: Nature medicine
Published: January 07, 2026

Increasing TET Expression and 5-Hydroxymethylcytosine Formation by a Carbocyclic 5-Aza-2'-deoxy-cytidine Antimetabolite.

Increasing TET Expression and 5-Hydroxymethylcytosine Formation by a Carbocyclic 5-Aza-2'-deoxy-cytidine Antimetabolite.

Journal: Angewandte Chemie (International ed. in English)
Published: November 26, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere
Published: September 09, 2025

ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia.

ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia.

Journal: Cell reports
Published: November 05, 2024

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

Journal: Journal of hematology & oncology
Published: November 05, 2024

Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.

Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.

Journal: Blood cancer discovery
Published: October 03, 2024

Phosphatidic acid phosphatase LPIN1 in phospholipid metabolism and stemness in hematopoiesis and AML.

Phosphatidic acid phosphatase LPIN1 in phospholipid metabolism and stemness in hematopoiesis and AML.

Journal: HemaSphere
Published: July 20, 2024

Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.

Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.

Journal: Blood
Published: July 12, 2024

Editorial Expression of Concern: Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.

Editorial Expression of Concern: Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.

Journal: Oncogene
Published: July 04, 2024

Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.

Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.

Journal: Leukemia
Published: May 14, 2024
Showing 1-12 of 105

Last Updated: 09/26/2026